Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin with Palliative Care in Demoralized Cancer Survivors
NCT05506982Phase 1Completed
- Sponsor
- Emory University
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in chronic pain, sponsored by Emory University. Primary endpoints: Incidence Of Treatment-Related Medical Grade 3 Or Higher Or Psychiatric Grade 4 Or Higher at 42 days and Evaluation of Feasibility Outcome To Assess Patient Retention in The Study at 42 days. Started Nov 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT05506982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506982.